Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

ClinicalTrials.gov ID: NCT01735630

Public ClinicalTrials.gov record NCT01735630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease

Study identification

NCT ID
NCT01735630
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
OPKO Health, Inc.
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
50 Years to 95 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2012 (Type not available)
Primary completion
May 2015 (Actual)
Completion
May 2015 (Actual)
Last update posted
Oct 21, 2019

2012 – 2015

United States locations

U.S. sites
57
U.S. states
25
U.S. cities
53
Facility City State ZIP Site status
TransitionTIL Investigational Site Birmingham Alabama 35294 —
TransitionTIL Investigational Site Phoenix Arizona 85004 —
TransitionTIL Investigational Site Phoenix Arizona 85006 —
TransitionTIL Investigational Site Encino California 91316 —
TransitionTIL Investigational Site Escondido California 92025 —
TransitionTIL Investigational Site Fresno California 93710 —
TransitionTIL Investigational Site Irvine California 92697 —
TransitionTIL Investigational Site Long Beach California 90806 —
TransitionTIL Investigational Site Los Alamitos California 90720 —
TransitionTIL Investigational Site Los Angeles California 90073 —
TransitionTIL Investigational Site Newport Beach California 92663 —
TransitionTIL Investigational Site Santa Ana California 92701 —
TransitionTIL Investigational Site Norwalk Connecticut 06851 —
TransitionTIL Investigational Site Washington D.C. District of Columbia 20057 —
TransitionTIL Investigational Site Atlantis Florida 33462 —
TransitionTIL Investigational Site Deerfield Beach Florida 33064 —
TransitionTIL Investigational Site Delray Beach Florida 33445 —
TransitionTIL Investigational Site Lake Worth Florida 33449 —
TransitionTIL Investigational Site Miami Florida 33137 —
TransitionTIL Investigational Site Oakland Park Florida 33334 —
TransitionTIL Investigational Site Orlando Florida 32806 —
TransitionTIL Investigational Site Ormond Beach Florida 32174 —
TransitionTIL Investigational Site Port Charlotte Florida 33952 —
TransitionTIL Investigational Site Sarasota Florida 34243 —
TransitionTIL Investigational Site Sunrise Florida 33351 —
TransitionTIL Investigational Site Columbus Georgia 31909 —
TransitionTIL Investigational Site Savannah Georgia 31419 —
TransitionTIL Investigational Site Springfield Illinois 62702 —
TransitionTIL Investigational Site Bangor Maine 04402 —
TransitionTIL Investigational Site Easton Maryland 21601 —
TransitionTIL Investigational Site Winchester Massachusetts 01890 —
TransitionTIL Investigational Site Ann Arbor Michigan 48105 —
TransitionTIL Investigational Site Paw Paw Michigan 49079 —
TransitionTIL Investigational Site Saint Paul Minnesota 55130 —
TransitionTIL Investigational Site Hattiesburg Mississippi 39401 —
TransitionTIL Investigational Site Stratford New Jersey 08084 —
TransitionTIL Investigational Site Rochester New York 14620 —
TransitionTIL Investigational Site Rochester New York 14623 —
TransitionTIL Investigational Site Charlotte North Carolina 28209 —
TransitionTIL Investigational Site Charlotte North Carolina 28211 —
TransitionTIL Investigational Site Durham North Carolina 27710 —
TransitionTIL Investigational Site Wilmington North Carolina 28401 —
TransitionTIL Investigational Site Winston-Salem North Carolina 27103 —
TransitionTIL Investigational Site Oklahoma City Oklahoma 73112 —
TransitionTIL Investigational Site Portland Oregon 97225 —
TransitionTIL Investigational Site Abington Pennsylvania 19001 —
TransitionTIL Investigational Site Jenkintown Pennsylvania 19046 —
TransitionTIL Investigational Site Norristown Pennsylvania 19401 —
TransitionTIL Investigational Site Philadelphia Pennsylvania 19104 —
TransitionTIL Investigational Site Philadelphia Pennsylvania 19107 —
TransitionTIL Investigational Site Pittsburgh Pennsylvania 15213 —
TransitionTIL Investigational Site North Charleston South Carolina 29406 —
TransitionTIL Investigational Site Port Royal South Carolina 29935 —
TransitionTIL Investigational Site Nashville Tennessee 37212 —
TransitionTIL Investigational Site DeSoto Texas 75115 —
TransitionTIL Investigational Site Richmond Virginia 23230 —
TransitionTIL Investigational Site Bellevue Washington 98007 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01735630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 21, 2019 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01735630 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →